Masimo Corporation (NASDAQ: MASI) is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) efforts. The optimism, led by a solid first-quarter 2024 performance and its solid product portfolio, is expected to contribute further. However, concerns regarding overdependence on its Signal Extraction Technology ("SET") unit and macroeconomic issues persist. Over the past year, this Zacks Rank #2 (Buy) company's shares have lost 7.1% against the industry's 6% growth. The S&P 500 has witnessed 17.6% growth in the said time frame. The renowned global provider of non-invasive monitoring systems has a market capitalization of $5.84 billion. The company projects 9.3% growth for 2025 and expects to maintain its strong performance going forward. Masimo's earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 4.7%. Image Source: Zacks Investment Research Let's delve deeper. Product Portfolio: We are optimistic about Masimo's healthcare business, which develops, manufactures and markets a variety of non-invasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Last month, Masimo introduced Sleep Halo, a powerful new feature, for its Masimo W1 Sport advanced health tracking wearable, intended for scientifically based sleep analysis. Sleep Halo is likely to offer overnight sleep data tracking with an unmatched 70,000+ daily measurements of second-by-second continuous health data. The company introduced White PerL, which is the latest from the Denon PerL product lines, in May. In February, Masimo received the FDA's clearance for MightySat Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available over-the-counter to consumers without a prescription. Research and Product Development: We are upbeat about ...